Skip to main content

Australia halts AstraZeneca vaccine for most people under 50

Thursday, April 8, 2021 | The Associated Press


In this image made from video, Australian Prime Minister Scott Morrison speaks during a news conference in Canberra, Australia, Thursday, April 8, 2021. Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50. (SBS via AP)

CANBERRA, Australia (AP) — Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50.

The announcement came after Australian drug regulators held a series of urgent meetings earlier in the day. The recommendation came after the European Medicines Agency said it had found a “possible link” between the shot and the rare blood clots, though regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people.

Prime Minister Scott Morrison said he'd received a series of recommendations from an advisory group on Thursday night, and that chief among them was that the Pfizer vaccine should now be adopted as the preferred vaccine for people aged under 50.

Morrison said the recommendations were made with an abundance of caution due to the rare but serious side effects, which have mostly been associated with younger people.

“We’ve been taking the necessary precautions based on the best possible medical advice,” Morrison said. “It has not been our practice to jump at shadows.”

The Australian Technical Advisory Group on Immunisation also recommended that people under 50 who had already received their first AstraZeneca shot should proceed with getting their second shot, as the medical advice indicated the rare blood clots only develop after the first dose.

The group said that only when the benefit clearly outweighs the risk should an initial AstraZeneca shot be given to someone under 50.

Healthcare workers under 50 who were due to receive the AstraZeneca vaccine will now be prioritized for the Pfizer vaccine, which will likely delay the inoculation process.

Indeed, under Australia’s vaccine strategy, most people were due to receive the AstraZeneca vaccine.

Opposition politicians said the European agency's findings highlighted the danger in Australia failing to secure vaccine deals with other suppliers.

The move in Australia came after British authorities recommended that the AstraZeneca vaccine not be given to adults under 30 where possible. Several other countries have also imposed limits.

Such restrictions are closely watched since the vaccine, which is cheaper and easier to store than many others, is critical to global immunization campaigns and is a pillar of the U.N.-backed program known as COVAX that aims to get vaccines to some of the world’s poorest countries.

Featured Article: What is a Real Estate Investment Trust (REIT)?


7 Stocks to Watch When Student Debt Forgiveness Gets Passed

Now that the Biden administration is fully in charge, student debt forgiveness has moved to the front burner. Consider these numbers. There is an estimated $1.7 trillion in student debt. The average student carries approximately $30,000 in student loans.

If $10,000 of student debt were to be canceled, there are estimates that one-third of borrowers (between 15 million to 16.3 million) would become debt-free. Of course, if the number hits $50,000 as some lawmakers are suggesting the impact would even greater.

Putting aside personal thoughts on the wisdom of pursuing this path, it has the potential to unleash a substantial stimulus into the economy.

And as an investor, it’s fair to ask where that money would go. After all, there’s no harm in having investors profit from this stimulus as well.

A counter-argument is that the absence of one monthly payment may not provide enough money to make an impact. However, Senator Elizabeth Warren referred to the effect student loans have in preventing many in the millennial and Gen-Z generations from pursuing big picture life goals such as buying a house, starting a business, or starting a family.

With that in mind, we’ve put together this special presentation that looks at 7 stocks that are likely to benefit if borrowers are set free from the burden of student loans.

View the "7 Stocks to Watch When Student Debt Forgiveness Gets Passed".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.1$39.69+0.9%3.93%25.61Hold$39.64
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.